大剂量表柔比星+环磷酰胺（HD-EC）用于转移性乳腺癌：一项剂量探索研究。 - Suppr | 超能文献

High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.

作者信息

Nagel G A, Beyer J H, Holtkamp W, Emrich D, Kneba M, Luig H, Marschner N, Rauschning W, Unger C, Wander H E

机构信息

Department of Internal Medicine, University Hospital Göttingen.

出版信息

Onkologie. 1988 Dec;11(6):287-8. doi: 10.1159/000216559.

DOI:10.1159/000216559

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.大剂量表柔比星+环磷酰胺（HD-EC）用于转移性乳腺癌：一项剂量探索研究。

Onkologie. 1988 Dec;11(6):287-8. doi: 10.1159/000216559.

2

Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.转移性乳腺癌患者中，与标准环磷酰胺、表柔比星和氟尿嘧啶（CEF）方案相比，加速强化CEF方案的疗效：意大利西北肿瘤学组-乳腺疾病组间多中心随机III期研究结果

J Clin Oncol. 2001 Apr 15;19(8):2213-21. doi: 10.1200/JCO.2001.19.8.2213.

3

High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: preliminary data of a phase-II study.高剂量表柔比星+环磷酰胺（HD-EC）治疗转移性乳腺癌：一项II期研究的初步数据。

Onkologie. 1988 Dec;11(6):289-91. doi: 10.1159/000216560.

4

[Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation].[在辅助和转移情况下，粒细胞集落刺激因子（G-CSF）在乳腺癌FEC（500/75/500mg/m²环磷酰胺/表柔比星/氟尿嘧啶）剂量强化化疗中的应用]

Gynakol Geburtshilfliche Rundsch. 1993;33 Suppl 1:301-2. doi: 10.1159/000272274.

5

Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.一项III期试验，比较表柔比星两种剂量水平联合环磷酰胺与环磷酰胺、甲氨蝶呤和氟尿嘧啶用于治疗淋巴结阳性乳腺癌的疗效。

J Clin Oncol. 2001 Jun 15;19(12):3103-10. doi: 10.1200/JCO.2001.19.12.3103.

6

5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.5-氟尿嘧啶、阿霉素、环磷酰胺（FAC）与5-氟尿嘧啶、表柔比星、环磷酰胺（FEC）治疗转移性乳腺癌的对比

Oncology. 1989;46(1):1-5. doi: 10.1159/000226671.

7

Chemotherapy and concomitant irradiation in inflammatory breast cancer.炎性乳腺癌的化疗与同步放疗

Anticancer Res. 2001 Jul-Aug;21(4B):3061-7.

8

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.在转移性乳腺癌中，基于表柔比星的剂量密集化疗优于强化静脉环磷酰胺、甲氨蝶呤和氟尿嘧啶方案：一项随机多国研究。

J Clin Oncol. 2001 Feb 15;19(4):943-53. doi: 10.1200/JCO.2001.19.4.943.

9

Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.10 个以上腋窝淋巴结阳性的乳腺癌患者中，密集型表阿霉素对比标准剂量表阿霉素/环磷酰胺序贯 CMF 方案化疗的随机试验结果（GABG-IV E-93）-德国乳腺癌辅助治疗协作组。

Eur J Cancer. 2010 Jan;46(1):84-94. doi: 10.1016/j.ejca.2009.10.001.

10

Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).转移性乳腺癌内分泌治疗6个月后，同时使用他莫昔芬（TAM）+环磷酰胺、表柔比星和氟尿嘧啶（CEF）与TAM+延迟6个月使用CEF的疗效比较——丹麦乳腺癌协作组（DBCG）的一项随机试验

Acta Oncol. 1996;35 Suppl 5:57. doi: 10.3109/02841869609083970.

引用本文的文献

1

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.表柔比星。对其药效学和药代动力学特性以及在癌症化疗中的治疗应用的综述。

Drugs. 1993 May;45(5):788-856. doi: 10.2165/00003495-199345050-00011.

2

Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicenter trial.以异环磷酰胺和表柔比星进行姑息性放化疗作为高危转移性乳腺癌的一线治疗。一项前瞻性多中心试验的结果

Cancer Chemother Pharmacol. 1990;26 Suppl:S74-7. doi: 10.1007/BF00685427.